Skip Nav Destination
Issues
1 November 2004
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
The Biology Behind
Featured Articles
Clinical Trials
Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule: A Phase I Pharmacokinetic and Food Effect Study
Emiliano Calvo; Anthony W. Tolcher; Lisa A. Hammond; Amita Patnaik; Johan S. de Bono; Irene A. Eiseman; Stephen C. Olson; Peter F. Lenehan; Heather McCreery; Patricia LoRusso; Eric K. Rowinsky
A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors
Stacy L. Moulder; John J. Mahany; Richard Lush; Caio Rocha-Lima; Michael Langevin; Karen J. Ferrante; Lisa Michele Bartkowski; Shama M. Kajiji; Dennis A. Noe; Simone Paillet; Daniel M. Sullivan
Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer
Yago Nieto; James J. Vredenburgh; Elizabeth J. Shpall; Scott I. Bearman; Peter A. McSweeney; Nelson Chao; David Rizzieri; Christina Gasparetto; Steve Matthes; Anna E. Barón; Roy B. Jones
Molecular Oncology, Markers, Clinical Correlates
Correlation of Molecular Genetics with Molecular and Morphological Imaging in Gliomas with an Oligodendroglial Component
Carol Walker; Daniel G. du Plessis; Diane Fildes; Brian Haylock; David Husband; Michael D. Jenkinson; Kathy A. Joyce; John Broome; Klaus Kopitski; Joanne Prosser; Trevor Smith; Sobhan Vinjamuri; Peter C. Warnke
Experimental Therapeutics, Preclinical Pharmacology
In vitro Stimulation with WT1 Peptide-Loaded Epstein-Barr Virus-Positive B Cells Elicits High Frequencies of WT1 Peptide-Specific T Cells with In vitro and In vivo Tumoricidal Activity
Ekaterina S. Doubrovina; Mikhail M. Doubrovin; Sangyull Lee; Jae-Hung Shieh; Glen Heller; Eric Pamer; Richard J. O’Reilly
Regular Articles
Clinical Trials
Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies
Paula M. Fracasso; Lori J. Goldstein; Dinesh P. de Alwis; Janet S. Rader; Matthew A. Arquette; Sherry A. Goodner; Lisa P. Wright; Carole L. Fears; Robert J. Gazak; Valerie A. M. Andre; Michael F. Burgess; Christopher A. Slapak; Jan H. M. Schellens
A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors
Samir E. Witta; Daniel L. Gustafson; A. Scott Pierson; Alexander Menter; Scott N. Holden; Michele Basche; Martha Persky; Cindy L. O’Bryant; Chan Zeng; Anna Baron; Michael E. Long; Amy Gibbs; Karen Kelly; Paul A. Bunn, Jr.; Daniel C. Chan; Patrick Pallansch; S. Gail Eckhardt
Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors: A Phase I Study
Charles M. Rudin; John L. Marshall; Chao Hui Huang; Hedy L. Kindler; Chuanbo Zhang; Deepak Kumar; Prafulla C. Gokhale; Joyce Steinberg; Steve Wanaski; Usha N. Kasid; Mark J. Ratain
Cancer Biology, Immunology, Cytokines
Research Articles
Molecular Oncology, Markers, Clinical Correlates
Increased Levels of Interleukin-10 in Serum from Patients with Hepatocellular Carcinoma Correlate with Profound Numerical Deficiencies and Immature Phenotype of Circulating Dendritic Cell Subsets
Susanne Beckebaum; Xia Zhang; Xiao Chen; Zhengya Yu; Andrea Frilling; Grzegorz Dworacki; Hans Grosse-Wilde; Christoph Erich Broelsch; Guido Gerken; Vito R. Cicinnati
Experimental Therapeutics, Preclinical Pharmacology
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.